Rakuten Securities Inc. Purchases 1,003 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Rakuten Securities Inc. raised its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 160.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,628 shares of the biopharmaceutical company’s stock after acquiring an additional 1,003 shares during the period. Rakuten Securities Inc.’s holdings in Royalty Pharma were worth $42,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of RPRX. Brooklyn Investment Group boosted its holdings in Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 876 shares during the period. Allworth Financial LP boosted its holdings in Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 877 shares during the period. Riverview Trust Co boosted its holdings in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,186 shares during the period. Fifth Third Bancorp boosted its holdings in Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 997 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 376 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Up 1.2 %

Shares of RPRX opened at $32.85 on Thursday. The company has a 50-day simple moving average of $31.31 and a 200-day simple moving average of $28.50. The firm has a market capitalization of $18.94 billion, a P/E ratio of 22.66, a P/E/G ratio of 2.31 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend was Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is 60.69%.

Analyst Ratings Changes

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.